Consistency of Response to Rimegepant for the Acute Treatment of Migraine: A Population and Participant-Level Analysis of a Prospective Real-World Observational Study (CONFIDENCE)
Abraham L, Urani A, Lambru G, Lipton RB, Goadsby PJ, Pozo-Rosich P, Fanning KM, Dai F, Hygge Blakeman K
IHC 2025
- 国际头痛学会年会 2025
| 偏头痛
Migraine Treatment Experience in Denmark: Results from a Nationwide Real World Data Study with 58,000 Respondents between 2021–2023
Schytz HW, Hauberg DS, Lønberg US, Jenkins A, Abraham L, Hygge Blakeman K, Spanggaard M, Olsen J, Bach C, Hansen TF
IHC 2025
- 国际头痛学会年会 2025
| 偏头痛
A Phase 4 Randomized Double-blind Placebo-Controlled Study of Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Ashina M, McAllister P, Ramirez LM, Nalpas C, Thiry A, Abraham L, Fountaine R, Fullerton T
IHC 2025
- 国际头痛学会年会 2025
| 偏头痛
Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Hispanic or Latino Adults: Post-hoc Analysis of 3 Randomized, Placebo-Controlled Clinical Trials
Vieira JR, Fajardo M, Abbott C, Sellix MT, Li J
IHC 2025
- 国际头痛学会年会 2025
| 偏头痛
